enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Multiple myeloma - Wikipedia

   en.wikipedia.org/wiki/Multiple_myeloma

   Multiple national cancer treatment guidelines recommend early palliative care for people with advanced multiple myeloma at the time of diagnosis and for anyone who has significant symptoms. [142] [143] Palliative care is appropriate at any stage of multiple myeloma and can be provided alongside curative treatment.

3. Myeloproliferative neoplasm - Wikipedia

   en.wikipedia.org/wiki/Myeloproliferative_neoplasm

   Tyrosine kinase inhibitors like imatinib have improved the prognosis of CML patients to near-normal life expectancy. [14] Recently, a JAK2 inhibitor, namely ruxolitinib, has been approved for use in primary myelofibrosis. [15] Trials of these inhibitors are in progress for the treatment of the other myeloproliferative neoplasms.

4. Cancer survival rates - Wikipedia

   en.wikipedia.org/wiki/Cancer_survival_rates

   The National Institute of Health (NIH) attributes the increase in the 5-year relative survival of prostate cancer (from 69% in the 1970s to 100% in 2006) to screening and diagnosis and due to the fact that men that participate in screening tend to be healthier and live longer than the average man and testing techniques that are able to detect ...

5. Smouldering myeloma - Wikipedia

   en.wikipedia.org/wiki/Smouldering_myeloma

   Smouldering myeloma is a disease classified as intermediate in a spectrum of step-wise progressive diseases termed plasma cell dyscrasias.In this spectrum of diseases, a clone of plasma cells secreting monoclonal paraprotein (also termed myeloma protein or M protein) causes the relatively benign disease of monoclonal gammopathy of undetermined significance.

6. Plasmacytoma - Wikipedia

   en.wikipedia.org/wiki/Plasmacytoma

   Most cases of SPB progress to multiple myeloma within 2–4 years of diagnosis, but the overall median survival for SPB is 7–12 years. 30–50% of extramedullary plasmacytoma cases progress to multiple myeloma with a median time of 1.5–2.5 years. 15–45% of SPB and 50–65% of extramedullary plasmacytoma are disease free after 10 years. [3]

7. Myelodysplastic syndrome - Wikipedia

   en.wikipedia.org/wiki/Myelodysplastic_syndrome

   The best prognosis is seen with RA and RARS, where some nontransplant patients live more than a decade (typical is on the order of three to five years, although long-term remission is possible if a bone-marrow transplant is successful). The worst outlook is with RAEB-T, where the mean life expectancy is less than one year.